Skip to main content
S&P 5007,743.98+0.28%DOW52,475.10+0.19%NASDAQ26,549.85+0.27%BTC$81,079.00+0.53%ETH$2,354.15+0.45%GOLD$4,051.400.00%OIL$102.03-0.73%
Smart Investors Daily
SID Premium
TM

NASDAQ · TMDX

TransMedics Group, Inc.

Healthcare · Medical - Devices

$66.90

Down-$2.83 (-4.06%)

Updated Oct 29, 2026, 5:24 AM

SID Score

3.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.37B
P/E ratio
47.56
Dividend yield
0.00%
52-week range
$60.11 – $135.28
Volume
1.18M
Avg. volume
933.82K

Price performance · TMDX

TMDX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 28, 2026

TMDX closed at $66.90 after 21 trading sessions, down 19.83% for the selected period.

Last close
$66.90
Period change
-19.83%
Period low
$66.90
Period high
$83.45
Daily close
View OHLC price history
TMDX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 28, 2026$69.02$69.98$66.68$66.901.18M
Oct 27, 2026$70.53$71.18$69.63$69.73826.61K
Oct 26, 2026$70.01$71.97$69.61$70.63847.93K
Oct 23, 2026$71.42$72.68$69.755$70.74790.1K
Oct 22, 2026$72.34$73.655$70.52$72.06627.7K
Oct 21, 2026$74.47$76.00$72.255$72.40685.95K
Oct 20, 2026$71.65$75.66$67.31$74.751.17M
Oct 19, 2026$71.16$72.81$70.5001$71.60657.14K
Oct 16, 2026$76.52$76.52$70.03$70.781.07M
Oct 15, 2026$74.41$77.34$74.41$76.521.13M
Oct 14, 2026$78.20$78.355$74.84$75.52892.07K
Oct 13, 2026$78.17$80.415$77.86$79.1351.16M
Oct 12, 2026$77.69$78.50$77.14$78.17491.98K
Oct 9, 2026$79.13$81.345$76.86$77.87733.74K
Oct 8, 2026$80.25$80.275$77.50$79.00949.6K
Oct 7, 2026$80.96$83.90$80.56$81.07962.66K
Oct 6, 2026$83.87$84.05$80.08$80.28570.85K
Oct 5, 2026$79.50$83.40$77.3706$82.99995.11K
Oct 2, 2026$79.81$80.85$77.14$79.7951.22M
Oct 1, 2026$83.92$84.24$78.02$78.64880.64K
Sep 30, 2026$84.87$84.87$81.55$83.45566.81K

Latest TMDX news

The latest Smart Investors Daily articles mentioning TMDX.

Stock researchCompany · Overview

TMDX research

Overview

Company profile and research snapshot.

Company profile

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$148.00
Implied upside
—
Analysts
20
TMDX recent ratings
DateFirmRatingTarget
Oct 13, 2026Canaccord GenuityBuy—
Oct 7, 2026BarclaysOverweight—
Sep 8, 2026TD CowenBuy—
Aug 5, 2026Piper SandlerOverweight—
Aug 5, 2026UBSNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

Yahoo · Oct 17, 2026

TransMedics Group (TMDX) Stock Looks Undervalued On Current Earnings

TransMedics Group has given shareholders a wild ride over the past few years, and after a sharp pullback the live question is whether the current share price lines up with the earnings the business is generating. With the stock well off its highs, investors are increasingly asking if today’s valuation fairly reflects what the company earns today rather than what it might earn someday. Over the past 5 years the TransMedics Group share price has gained 157.9%, which puts real pressure on the...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By